|Day Low/High||51.89 / 53.96|
|52 Wk Low/High||46.52 / 135.43|
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.
Ultragenyx CEO Emil Kakkis, M.D. Ph.D., Receives 2016 Lysosomal Disease Network Award for Innovation and Achievement
Leerink began coverage of Ultragenyx Pharmaceutical (RARE) stock with an 'outperform' rating and $80 price target on Friday morning.
Substantial Reduction in Bone Disease Demonstrated With Two Different Instruments
Pivotal Phase 3 Movement Disorder Study to Initiate Mid-2016